{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:20:07Z","timestamp":1789820407996,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.medmal.2016.07.006","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T01:32:58Z","timestamp":1487813578000},"page":"3-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Multidrug and extensively drug-resistant tuberculosis"],"prefix":"10.1016","volume":"47","author":[{"given":"T.","family":"Maitre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Jarlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Veziris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Sougakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Brossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cambau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mougari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Raskine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4588","key":"10.1016\/j.medmal.2016.07.006_bib0005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/bmj.2.4588.1009","article-title":"Streptomycin resistance in pulmonary tuberculosis","volume":"2","author":"Crofton","year":"1948","journal-title":"Br Med J"},{"issue":"15","key":"10.1016\/j.medmal.2016.07.006_bib0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/jama.1996.03540150031027","article-title":"A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes","volume":"276","author":"Frieden","year":"1996","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.medmal.2016.07.006_bib0015","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMc0805644","article-title":"Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis","volume":"359","author":"Cox","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.medmal.2016.07.006_bib0020","doi-asserted-by":"crossref","first-page":"e18327","DOI":"10.1371\/journal.pone.0018327","article-title":"Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy","volume":"6","author":"Colijn","year":"2011","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.medmal.2016.07.006_bib0025","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.medmal.2016.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2016.07.006_bib0035","series-title":"Global tuberculosis report\u00a02015","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.medmal.2016.07.006_bib0040","series-title":"Rapport d\u2019activit\u00e9 pour l\u2019ann\u00e9e\u00a02013","author":"Centre national de r\u00e9f\u00e9rence des mycobact\u00e9ries et de la r\u00e9sistance des mycobact\u00e9ries aux antituberculeux (CNR-MyRMA)","year":"2014"},{"key":"10.1016\/j.medmal.2016.07.006_bib0045","article-title":"Antituberculosis drug resistance in France in\u00a02013","author":"Centre national de r\u00e9f\u00e9rence des mycobact\u00e9ries et de la r\u00e9sistance des mycobact\u00e9ries aux antituberculeux (CNR-MyRMA)","year":"2015","journal-title":"BEH"},{"key":"10.1016\/j.medmal.2016.07.006_bib0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2807\/1560-7917.ES2013.18.33.20555","article-title":"A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union","volume":"18","author":"Bernard","year":"2013","journal-title":"Euro Surveill"},{"issue":"18","key":"10.1016\/j.medmal.2016.07.006_bib0055","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1001\/jama.300.18.2153","article-title":"Extensively drug-resistant tuberculosis in the United States, 1993\u20132007","volume":"300","author":"Shah","year":"2008","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.medmal.2016.07.006_bib0060","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.medmal.2016.07.006_bib0065","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1164\/rccm.200911-1656OC","article-title":"Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis","volume":"182","author":"Kim","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.medmal.2016.07.006_bib0070","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/cid\/civ910","article-title":"Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance","volume":"62","author":"Cegielski","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.medmal.2016.07.006_bib0075","first-page":"12941","article-title":"Efficacy and safety profile of linezolid in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: a sytematic review and meta-analysis","volume":"22","author":"Agyeman","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"23","key":"10.1016\/j.medmal.2016.07.006_bib0080","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":"The diarylquinoline TMC207 for multidrug-resistant tuberculosis","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.medmal.2016.07.006_bib0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.medmal.2016.07.006_bib0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1164\/ajrccm.160.2.9901012","article-title":"Outcome of multi-drug-resistant tuberculosis in France","volume":"160","author":"Flament-Saillour","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.medmal.2016.07.006_bib0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ijantimicag.2006.11.023","article-title":"An intervention programme for the management of multidrug-resistant tuberculosis in France","volume":"29","author":"Uffredi","year":"2007","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.medmal.2016.07.006_bib0100","first-page":"305","article-title":"Trends in tuberculosis \u2013\u00a0United States, 2005","volume":"55","author":"Centers for Disease Control Prevention (CDC)","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-3","key":"10.1016\/j.medmal.2016.07.006_bib0105","first-page":"1","article-title":"Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force","volume":"58","author":"Centers for Disease Control Prevention (CDC)","year":"2009","journal-title":"MMWR Recomm Rep"},{"issue":"9547","key":"10.1016\/j.medmal.2016.07.006_bib0110","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","article-title":"Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa","volume":"368","author":"Gandhi","year":"2006","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.medmal.2016.07.006_bib0115","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1183\/09031936.00155708","article-title":"Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB","volume":"33","author":"Kliiman","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.medmal.2016.07.006_bib0120","first-page":"217","article-title":"Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation","volume":"27","author":"Canetti","year":"1963","journal-title":"Rev Tuberc Pneumol (Paris)"},{"key":"10.1016\/j.medmal.2016.07.006_bib0125","series-title":"Tuberculoses \u00e0 bacilles r\u00e9sistants\u00a0: diagnostic et prise en charge","author":"Haut Conseil de la Sant\u00e9 publique","year":"2014"},{"key":"10.1016\/j.medmal.2016.07.006_bib0130","first-page":"CD009593","article-title":"Xpert\u00ae MTB\/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults","volume":"1","author":"Steingart","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.medmal.2016.07.006_bib0135","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1183\/09031936.00061808","article-title":"GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis","volume":"32","author":"Ling","year":"2008","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.medmal.2016.07.006_bib0140","first-page":"260","article-title":"Performance of MTBDR plus for detecting high\/low levels of Mycobacterium tuberculosis resistance to isoniazid","volume":"13","author":"Brossier","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.medmal.2016.07.006_bib0145","doi-asserted-by":"crossref","first-page":"e55292","DOI":"10.1371\/journal.pone.0055292","article-title":"Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using GenoType MTBDRsl assay: a meta-analysis","volume":"8","author":"Feng","year":"2013","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1016\/j.medmal.2016.07.006_bib0150","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1128\/JCM.01947-09","article-title":"Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates","volume":"48","author":"Brossier","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.medmal.2016.07.006_bib0155","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1183\/09031936.00037207","article-title":"A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995\u20132004","volume":"30","author":"Khue","year":"2007","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.medmal.2016.07.006_bib0160","first-page":"409","article-title":"Multidrug-resistant tuberculosis without HIV infection: success with individualised therapy","volume":"10","author":"Escudero","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.medmal.2016.07.006_bib0165","series-title":"WHO treatment guidelines for drug-resistant tuberculosis (update)","first-page":"216AD","author":"World Health Organization","year":"2016"},{"issue":"10","key":"10.1016\/j.medmal.2016.07.006_bib0170","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1164\/rccm.200308-1159OC","article-title":"Treatment and outcome analysis of 205\u00a0patients with multidrug-resistant tuberculosis","volume":"169","author":"Chan","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.medmal.2016.07.006_bib0175","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"10.1016\/j.medmal.2016.07.006_bib0180","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.medmal.2016.07.006_bib0185","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/cid\/civ027","article-title":"Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China","volume":"60","author":"Tang","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"5707","key":"10.1016\/j.medmal.2016.07.006_bib0190","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.medmal.2016.07.006_bib0195","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1128\/AAC.00181-07","article-title":"In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor","volume":"51","author":"Huitric","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.medmal.2016.07.006_bib0200","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit\u00a0c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.medmal.2016.07.006_bib0205","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.00898-06","article-title":"Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis","volume":"51","author":"Ibrahim","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9846","key":"10.1016\/j.medmal.2016.07.006_bib0210","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0140-6736(12)61080-0","article-title":"14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial","volume":"380","author":"Diacon","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.medmal.2016.07.006_bib0215","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.06126-11","article-title":"Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance","volume":"56","author":"Diacon","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.medmal.2016.07.006_bib0220","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.medmal.2016.07.006_bib0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1415332","article-title":"Delamanid for extensively drug-resistant tuberculosis","volume":"373","author":"Gupta","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.medmal.2016.07.006_bib0230","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1001\/jama.293.22.2767","article-title":"Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally","volume":"293","author":"Dye","year":"2005","journal-title":"JAMA"},{"issue":"9731","key":"10.1016\/j.medmal.2016.07.006_bib0235","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","article-title":"Global tuberculosis drug development pipeline: the need and the reality","volume":"375","author":"Ma","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.medmal.2016.07.006_bib0240","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.medmal.2016.07.006_bib0245","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5588\/ijtld.14.0535","article-title":"High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon","volume":"19","author":"Kuaban","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"10.1016\/j.medmal.2016.07.006_bib0250","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1128\/AAC.47.10.3117-3122.2003","article-title":"Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo","volume":"47","author":"Veziris","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.medmal.2016.07.006_bib0255","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/rccm.201304-0753OC","article-title":"Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice","volume":"188","author":"Grosset","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.medmal.2016.07.006_bib0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1473-3099(11)70244-4","article-title":"Surgical treatment of drug-resistant tuberculosis","volume":"12","author":"Kempker","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medmal.2016.07.006_bib0265","first-page":"ciw002","article-title":"Surgery as an adjunctive treatment for multi-drug resistant tuberculosis: an individual patient data meta-analysis","author":"Fox","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2016.07.006_bib0270","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis","author":"Pym","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.medmal.2016.07.006_bib0275","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.medmal.2015.12.008","article-title":"XDR-tuberculosis in France: community transmission due to non-compliance with isolation precautions","volume":"46","author":"Lafeuille","year":"2016","journal-title":"Med Mal Infect"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X16301433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X16301433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T01:14:50Z","timestamp":1759972490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X16301433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S0399077X16301433"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2016.07.006","relation":{},"ISSN":["0399-077X"],"issn-type":[{"value":"0399-077X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multidrug and extensively drug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2016.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}